Active substance
Clotrimazole
- SFDA 26
- US FDA 36
- Health Canada 22
- US price lines 20
- NHS prices 11
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CANESTEN CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 16.15 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| CANESTEN SOLUTION 1% | 1 % | Cutaneous solution · Topical | 1 Dropper Container | SAR 16.15 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| CANESTEN VAGINAL TAB 100MG | 100 mg | Vaginal tablet · Vaginal use | 6 Blister | SAR 21.70 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| CANESTEN-1 VAG. CREAM 10% | 10 % | Vaginal cream · Vaginal use | 1 Tube | SAR 29.20 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| CANESTEN-1 VAG.TAB 500MG WITH APPLICATOR | 500 mg | Vaginal tablet · Vaginal use | 1 Blister | SAR 21.70 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| CLOTREX | 1 % | Oral drops · Auricular use | 1 Dropper Container | SAR 10.80 | Generic · OTC | HAYAT PHARMACEUTICAL INDUSTRIES | Valid |
| CLOTRIM 100 MG VAGINAL TABLETS | 100 mg | Tablet · Vaginal use | 6 Blister | SAR 14.90 | Generic · OTC | JORDAN RIVER PHARMACEUTICAL INDUSTRIES | Valid |
| CLOTRIZOLE 100MG VAGINAL TABLETS | 100 mg | Tablet · Vaginal use | 6 Blister | SAR 12.55 | Generic · OTC | BATTERJEE PHARMACETICAL FACTORY | Valid |
| DERMATIN CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 10.00 | Generic · OTC | PHARCO PHARMACEUTICAL | Valid |
| DERMATIN SOLUTION 1% | 1 % | Solution · Topical | 1 Bottle | SAR 14.50 | Generic · OTC | PHARCO PHARMACEUTICAL | Valid |
| FUNGO 1% CREAM | 1 g | Cream · Topical | 1 Tube | SAR 7.05 | Generic · OTC | BATTERJEE PHARMACETICAL FACTORY | Valid |
| OPIZOLE 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 5.90 | Generic · OTC | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| OTOZOL 1% EAR DROP | 1 % | Ear drops · Auricular use | 1 Dropper Container | SAR 8.30 | Generic · OTC | Amman Pharmaceutical Industries (API) | Valid |
| CANESTEN CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 16.15 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| CANESTEN SOLUTION 1% | 1 % | Solution · Topical | 1 Dropper Container | SAR 16.15 | NCE · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| CANESTEN VAGINAL TAB 100MG | 100 mg | Tablet · Vaginal use | 6 Blister | SAR 17.95 | NCE · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| CANESTEN-1 VAG. CREAM 10% | 10 % | Vaginal cream · Vaginal use | 1 Tube | SAR 29.20 | NCE · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| CANESTEN-1 VAG.TAB 500MG WITH APPLICATOR | 500 mg | Tablet · Vaginal use | 1 Blister | SAR 17.95 | NCE · OTC | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| CLOZOLE 0.1% TOPICAL CREAM | 1 % | Cream · Topical | 1 Tube | SAR 11.90 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CLOZOLE 1% TOPICAL SOLUTION | 1 % | Cutaneous liquid · Topical | 1 Bottle | SAR 13.50 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CLOZOLE VAGINAL CREAM | 10 % | Cream · Vaginal use | 1 Tube | SAR 22.85 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| DERMATIN 1% POWDER | 1 % | Powder · Topical | 1 Bottle | SAR 5.15 | Generic · OTC | PHARCO PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| MEDSTEN 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 11.75 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| MICOTER 1% SOLUTION | 1 % | Oral solution · Oral use | 1 Bottle | SAR 10.75 | Generic · OTC | ALCON CUSI | Withdrawn by MAH · Not Marketed |
| MICOTER CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 11.10 | Generic · OTC | ALCON CUSI | Withdrawn by MAH · Not Marketed |
1 more — full table
Indications — CHI Daman Drug Formulary
FUNGAL INFECTIONS OF THE GENITAL TRACT - CANDIDIASIS OF OTHER UROGENITAL SITES; MATERNAL AND CHILD HEALTHCARE- VAGINAL CANDIDIASIS IN PREGNANCY; RENAL TRANSPLANT; TINEA CORPORIS, TINEA CRURIS, AND TINEA PEDIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MYCELEX | 1% | solution · topical | BAYER HLTHCARE | Over-the-counter | 15 Jan 1979 |
| LOTRIMIN AF | 1% | cream · topical | SCHERING PLOUGH | Over-the-counter | 27 Oct 1989 |
| LOTRIMIN AF | 1% | lotion · topical | SCHERING PLOUGH | Over-the-counter | 27 Oct 1989 |
| LOTRIMIN AF | 1% | solution · topical | SCHERING PLOUGH | Over-the-counter | 27 Oct 1989 |
| CLOTRIMAZOLE | 1% | cream · vaginal | ENCUBE | Over-the-counter | 16 Jul 1993 |
| CLOTRIMAZOLE | 1% | cream · topical | SUN PHARMA CANADA | Prescription | 31 Aug 1993 |
| CLOTRIMAZOLE | 1% | solution · topical | TEVA | Prescription | 28 Feb 1995 |
| CLOTRIMAZOLE | 1% | cream · vaginal | SUN PHARMA CANADA | Over-the-counter | 4 Dec 1995 |
| CLOTRIMAZOLE | 1% | solution · topical | SUN PHARMA CANADA | Prescription | 29 Jul 1996 |
| TRIVAGIZOLE 3 | 2% | cream · vaginal | SUN PHARMA CANADA | Over-the-counter | 12 Apr 2000 |
| CLOTRIMAZOLE | 10MG | troche/lozenge · oral | HIKMA PHARMS | Prescription | 29 Jul 2004 |
| CLOTRIMAZOLE | 10MG | troche/lozenge · oral | PADAGIS US | Prescription | 28 Oct 2005 |
| CLOTRIMAZOLE | 1% | cream · topical | FOUGERA PHARMS | Prescription | 2 Sep 2008 |
| CLOTRIMAZOLE | 1% | cream · topical | GLENMARK PHARMS | Prescription | 3 Aug 2010 |
| CLOTRIMAZOLE | 1% | solution · topical | NOVITIUM PHARMA | Prescription | 15 Feb 2019 |
| CLOTRIMAZOLE | 1% | solution · topical | TP ANDA HOLDINGS | Prescription | 25 Jul 2019 |
| CLOTRIMAZOLE | 1% | solution · topical | SCIEGEN PHARMS | Prescription | 16 Oct 2023 |
| CLOTRIMAZOLE | 10MG | troche/lozenge · oral | THINQ PHARM-CRO PVT | Prescription | 29 Feb 2024 |
| CLOTIC | 1% | solution/drops · otic | CARWIN PHARM ASSOC | Prescription | 26 Sep 2025 |
| LOTRIMIN | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · topical | SCHERING PLOUGH | Discontinued | 3 Feb 1975 |
| LOTRIMIN | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | SCHERING PLOUGH | Discontinued | 18 Mar 1975 |
| GYNE-LOTRIMIN | 100MG | tablet · vaginal | BAYER HEALTHCARE LLC | Discontinued | 24 Mar 1976 |
| GYNE-LOTRIMIN | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · vaginal | BAYER HEALTHCARE LLC | Discontinued | 8 Nov 1978 |
| MYCELEX | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · topical | BAYER HLTHCARE | Discontinued | 15 Jan 1979 |
| MYCELEX | 1% | cream · topical | BAYER HEALTHCARE LLC | Discontinued | 15 Jan 1979 |
11 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CANESTEN 1 DAY INTERNAL CREAM | 02150883 | 10 % / W/W | CREAM · VAGINAL | BAYER INC |
| CANESTEN 1% TOPICAL CREAM | 02150867 | 1 % / % | CREAM · TOPICAL | BAYER INC |
| CANESTEN 3 DAY INTERNAL CREAM | 02150905 | 2 % / W/W | CREAM · VAGINAL | BAYER INC |
| CANESTEN 6 DAY INTERNAL CREAM | 02150891 | 1 % / W/W | CREAM · VAGINAL | BAYER INC |
| CANESTEN COMBI 1 DAY | 02264102 | 1 % / W/W; 500 MG / VTAB | CREAM; VAGINAL TABLET; KIT · VAGINAL; TOPICAL | BAYER INC |
| CANESTEN COMBI 1 DAY INTERNAL + EXTERNAL CREAMS | 02230509 | 10 % / W/W; 1 % / W/W | KIT; CREAM · TOPICAL; VAGINAL | BAYER INC |
| CANESTEN COMBI 1 DAY SOFT CAPSULE + EXTRA STRENGTH EXTERNAL CREAM | 02547260 | 500 MG / CAP; 2 % / W/W | CREAM; KIT; VAGINAL CAPSULE · VAGINAL; TOPICAL | BAYER INC |
| CANESTEN COMBI 3 DAY | 02264099 | 1 % / W/W; 200 MG / VTAB | VAGINAL TABLET; KIT; CREAM · VAGINAL; TOPICAL | BAYER INC |
| CANESTEN COMFORTAB 1 | 02150859 | 500 MG | VAGINAL TABLET · VAGINAL | BAYER INC |
| CANESTEN COMFORTAB 3 | 02150840 | 200 MG | VAGINAL TABLET · VAGINAL | BAYER INC |
| CANESTEN EXTERNAL ANTIFUNGAL CREAM | 02239432 | 1 % / W/W | CREAM · TOPICAL | BAYER INC |
| CANESTEN EXTERNAL CREAM | 02311720 | 1 % | CREAM · VAGINAL; TOPICAL | BAYER INC |
| CANESTEN EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM | 02490927 | 2 % / W/W | CREAM · TOPICAL | BAYER INC |
| CANESTEN SOFT CAPSULE 1 | 02547252 | 500 MG | VAGINAL CAPSULE · VAGINAL | BAYER INC |
| CLOTRIMADERM TOPICAL | 00812382 | 1 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| CLOTRIMADERM VAGINAL 3 | 00812374 | 2 % / W/W | CREAM · VAGINAL | TARO PHARMACEUTICALS INC |
| CLOTRIMADERM VAGINAL 6 | 00812366 | 1 % / W/W | CREAM · VAGINAL | TARO PHARMACEUTICALS INC |
| CLOTRIMAZOLE EXTERNAL ANTIFUNGAL CREAM | 02462397 | 1 % / W/W | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| CLOTRIMAZOLE EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM | 02503360 | 2 % / W/W | CREAM · VAGINAL | TARO PHARMACEUTICALS INC |
| CLOTRIMAZOLE TOPICAL | 02229380 | 1 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| CLOTRIMAZOLE VAGINAL 3 | 02229379 | 2 % | CREAM · VAGINAL | TARO PHARMACEUTICALS INC |
| CLOTRIMAZOLE VAGINAL 6 | 02229378 | 1 % | CREAM · VAGINAL | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CLOTRIMAZOLE 1% SOLUTION | $2.01789 | per ML | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% SOLUTION | $2.742 | per ML | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% SOLUTION | $0.42569 | per ML | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.08208 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.04735 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.06293 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.11771 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.19892 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.13296 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.16222 | per GM | 23 Sep 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.34307 | per GM | 22 Apr 2026 |
| US NADAC | CLOTRIMAZOLE 1% TOPICAL CREAM | $0.21853 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Clotrimazole 1% cream | £1.52 | 20 gram | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 1% cream | £3.80 | 50 gram | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 1% solution | £2.54 | 20 ml | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 1% spray | £5.00 | 40 ml | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 10% cream and Clotrimazole 2% cream | £11.96 | 1 pack | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 10% vaginal cream | £8.36 | 5 gram | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 100mg pessaries | £3.85 | 6 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 2% cream | £6.41 | 20 gram | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 200mg pessaries | £3.41 | 3 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 500mg pessaries | £8.54 | 1 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Clotrimazole 500mg pessary and Clotrimazole 2% cream | £5.73 | 1 pack | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.3. Antifungal medicines · core
Vulvovaginal candidosis
Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
Safety signals and safety-related labeling changes
- US FDA 14 Jun 2019 LOTRISONE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 25 Aug 2016 TRIVAGIZOLE 3 — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Combinations containing Clotrimazole
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.